133 results on '"Habermann, Thomas M."'
Search Results
2. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma
3. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)
4. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
5. Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma
6. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
7. Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma
8. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
9. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma
10. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma
11. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era
12. Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia
13. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement
14. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma
15. Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma
16. Testicular FDG‐PET / CT uptake threshold in aggressive lymphomas
17. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
18. The clinical spectrum of Castlemanʼs disease
19. Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat
20. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
21. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients
22. Inherited genetic variation and overall survival following follicular lymphoma
23. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma
24. ASH 2010 meeting report-top 10 clinically oriented abstracts in lymphoma
25. Impact of MYD88 L265P mutation status on histological transformation of Waldenström Macroglobulinemia
26. ASH 2009 meeting report—Top 10 clinically oriented abstracts in lymphoma
27. Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study
28. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma
29. mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)
30. Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma
31. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas
32. Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
33. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018
34. Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma
35. The association of physical activity before and after lymphoma diagnosis with survival outcomes
36. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.
37. MYD88mutation status does not impact overall survival in Waldenström macroglobulinemia
38. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
39. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy
40. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
41. Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018.
42. Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas.
43. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
44. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison tode novoHodgkin lymphoma
45. Prevalence, clinical characteristics and prognosis of EBV‐positive follicular lymphoma.
46. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
47. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
48. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
49. Cytogenetic findings in 21 cases of peripheral T-Cell lymphoma
50. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.